Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Shares Issued (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Shares Issued for 7 consecutive years, with -$2.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued fell 33.92% to -$2.9 million in Q4 2025 year-over-year; TTM through Sep 2025 was $731000.0, a 100.36% increase, with the full-year FY2023 number at $33.6 million, up 992.68% from a year prior.
  • Shares Issued was -$2.9 million for Q4 2025 at Beam Therapeutics, down from $412000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $732.2 million in Q3 2021 to a low of -$203.0 million in Q4 2023.
  • A 5-year average of $46.7 million and a median of $1.4 million in 2022 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: soared 131363.2% in 2021, then tumbled 462.03% in 2022.
  • Beam Therapeutics' Shares Issued stood at $20.2 million in 2021, then crashed by 462.03% to -$73.3 million in 2022, then plummeted by 176.94% to -$203.0 million in 2023, then soared by 98.94% to -$2.2 million in 2024, then plummeted by 33.92% to -$2.9 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Shares Issued are -$2.9 million (Q4 2025), $412000.0 (Q3 2025), and $1.8 million (Q2 2025).